Androgen deprivation therapy continues to be widely used for the treatment of prostate
cancer despite the appearance of new‐generation androgen‐receptor targeting drugs after …

The Medical Journal of Australia Page 1 MJA • Volume 194 Number 6 • 21 March 2011 301
GUIDELINES The Medical Journal of Australia ISSN: 0025729X 21 March 2011 194 6 301-306 …

Androgen deprivation therapy is commonly employed for the treatment of non-metastatic
prostate cancer as primary or adjuvant treatment. The skeleton is greatly compromised in …

Prostate cancer is the most common solid-organ cancer in men, with a lifetime risk of 1 in 9.
1 The contemporary 5-year relative survival rate for men with all stages of prostate cancer …

Androgen-deprivation therapy (ADT) has become a standard of care in the management of
advanced prostate cancer or as an adjunct therapy. However, ADT is associated with a well …

Breast cancer and prostate cancer are sex hormone-dependent cancers, and estrogen or
androgen suppression therapy is the standard treatment. Cancer treatment-induced bone …

Aims To make recommendations with respect to bone health and bone-targeted therapies in
men with prostate cancer. Materials and methods A systematic review was carried out by …

Androgen deprivation therapy and aromatase inhibitors are known to cause a decrease in
bone mineral density and an increase in fractures. Patients receiving these treatments have …

Introduction Androgen deprivation therapy (ADT) is commonly utilized in the management of
both localized and advanced adenocarcinoma of the prostate. The use of ADT is associated …

Osteoporosis in men : Current Opinion in Rheumatology Osteoporosis in men : Current
Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe Get new issue …